E
XENE icon

Ergoteles’s Xenon Pharmaceuticals XENE Stock Holding History

Ergoteles’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,516
Closed -$533K – 1805
2022
Q4 		$533K Buy
+13,516
New +$492K 0.02% 677

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Ergoteles's XENE Position: Q1 2023 in Review

Ergoteles sold out of Xenon Pharmaceuticals (XENE) in Q1 2023, closing a stake of 13,516 shares — an estimated $533K sold.

Ergoteles first reported a position in XENE in Q4 2022 and held it in 1 quarter. The position peaked at $533K in Q4 2022. 163 funds tracked by Wall St. Rank hold XENE as of Q1 2023.

  • Ergoteles reported no remaining Xenon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 13,516 Xenon Pharmaceuticals shares in Q1 2023, an estimated $533K.
  • Ergoteles first reported a position in Xenon Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Ergoteles's Xenon Pharmaceuticals position peaked at $533K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.